Table 3 Number of subjects categorized according to time spent in remission divided by subject-specific follow-up duration, for each of the remission criteria tested
From: Sustained rheumatoid arthritis remission is uncommon in clinical practice
All subjects in BRASS with ≥2 years of follow-up | |||||
|---|---|---|---|---|---|
Time in remission (%) | DAS28-CRP < 2.6 N= 871a | DAS28-CRP < 2.3 N= 871a | SDAI N= 871a | CDAI N= 871a | ACR/EULAR N= 871a |
0 | 326 (37%) | 401 (46%) | 599 (69%) | 610 (70%) | 634 (73%) |
1-25 | 130 (15%) | 146 (17%) | 94 (11%) | 30 (3%) | 87 (10%) |
26-50 | 196 (23%) | 163 (19%) | 108 (12%) | 127 (15%) | 101 (12%) |
51-75 | 121 (14%) | 102 (12%) | 52 (6%) | 66 (8%) | 39 (4%) |
76-99 | 52 (6%) | 30 (3%) | 10 (1%) | 17 (2%) | 7 (1%) |
100 | 46 (5%) | 29 (3%) | 8 (1%) | 21 (2%) | 3 (0.3%) |
Overall mean time in remission | 31% | 24% | 12% | 15% | 10% |
Selected population of subjects in BRASS | |||||
Time in remission (%) | DAS28-CRP < 2.6 N = 309 b | DAS28-CRP < 2.3 N = 275 b | SDAI N = 168 b | CDAI N = 170 b | ACR/EULAR N = 158 b |
1-25 | 77 (25%) | 89 (32%) | 58 (35%) | 54 (32%) | 60 (38%) |
26-50 | 133 (43%) | 111 (40%) | 62 (37%) | 72 (42%) | 64 (41%) |
51-75 | 49 (16%) | 37 (13%) | 30 (18%) | 24 (14%) | 18 (11%) |
76-99 | 28 (9%) | 21 (8%) | 6 (4%) | 7 (4%) | 8 (5%) |
100 | 22 (7%) | 17 (6%) | 12 (7%) | 13 (8%) | 8 (5%) |
Overall mean time in remission | 48% | 45% | 44% | 44% | 42% |